XC-130

XC-130
Clinical data
Other namesXC130; XC130-A10H
Routes of
administration		Oral[1][2][3]
Drug classDopamine receptor agonist; Antiparkinsonian agent

XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease.[1][4][2][3] It is taken orally.[1][2][3]

The drug is a dopamine D2 receptor partial agonist, a dopamine D3 receptor antagonist, an α1A-adrenergic receptor antagonist, and a serotonin 5-HT1B, 5-HT2A, and 5-HT2B receptor antagonist.[2] Its potency as a dopamine D2 receptor agonist is similar to that of lisuride.[2] XC-130 produces antiparkinsonian-like effects in animals.[3] Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D3 agonism), vasoconstriction (related to α1A-adrenergic and 5-HT1B agonism), hallucinogenic effects (related to 5-HT2A agonism), and cardiac valvulopathy (related to 5-HT2B agonism).[2] It has a notably longer elimination half-life than the relatively short-acting lisuride.[2] The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile.[2][3]

XC-130 is under development by Xoc Pharmaceuticals.[1][4] As of November 2022, it is in phase 1/2 clinical trials.[1][4] The chemical structure of XC-130 does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "XC 130". AdisInsight. 28 November 2022. Retrieved 25 January 2026.
  2. ^ a b c d e f g h Guzman M, Borland S, Fishman R, Armer T (13 April 2021). "In Vitro Profile of a Novel Long Lasting Dopamine Agonist Designed to Optimize Efficacy and Safety (4465)". Neurology. 96 (15_supplement) 4465. doi:10.1212/WNL.96.15_supplement.4465. ISSN 0028-3878. Retrieved 25 January 2026.
  3. ^ a b c d e Borland S, Guzman M, Fishman R (13 April 2021). "Assessment of a Novel Long Lasting Dopamine Agonist in the Unilateral 6-OHDA Lesion Model of Parkinson's Disease (4480)". Neurology. 96 (15_supplement) 4480. doi:10.1212/WNL.96.15_supplement.4480. ISSN 0028-3878. Retrieved 25 January 2026.
  4. ^ a b c "Delving into the Latest Updates on XC130-A10H with Synapse". Synapse. 8 May 2025. Retrieved 25 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.